Curevo Vaccine has announced the closing of a $110 million Series B round to advance the development of their shingles vaccine, amezosvatein, following successful Phase 2 study results. The round was led by new investor Medicxi and joined by other international investment funds.
Company Information
Company
Curevo
Location
Bothell, Washington, United States
About
Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.
BothellBiotechnologyHealthcareMobileSportsPlatforms